Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for
patients with certain haematological cancers, with multiple CAR T cell products currently …

Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with
clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell …

Background Odronextamab is a hinge-stabilised, fully human IgG4-based CD20× CD3
bispecific antibody that binds CD3 on T cells and CD20 on B cells. We aimed to evaluate the …

Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma
(NHL), comprises a heterogeneous group of diseases with different biology, clinical …

Immune cell engagers are engineered antibodies with at least one arm binding a tumor-
associated antigen and at least another one directed against an activating receptor in …

Background Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive
cancer with a median overall survival of less than 6 months. We aimed to assess the …

CD19-directed chimeric antigen receptor–modified (CAR T) T cells achieve durable
remissions in about 30% to 40% of relapsed/refractory large B-cell lymphomas. T-cell …

Two autologous anti‐CD19 chimeric antigen receptors (CAR) T cells (axicabtagene
ciloleucel [axi‐cel] and tisagenlecleucel [tisa‐cel]) are commercially approved in Europe for …

Abstract In the United States the increasing number of Food and Drug Administration (FDA)-
approved, innovative, and potentially effective commercial cancer therapies pose a …